Kestra Medical Technologies (KMTS) Depreciation & Amortization (CF) (2024 - 2026)

Kestra Medical Technologies (KMTS) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 26.63% year-over-year to $2.3 million; the TTM figure through Apr 2026 stood at $8.7 million (up 9.3% YoY), while the FY2026 annual figure was $8.7 million, up 9.3% from the prior year.
• Depreciation & Amortization (CF) climbed to $2.3 million in Q2 2026 per KMTS's latest filing, from $2.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.5 million in Q2 2024 and bottomed at $1.8 million in Q2 2025.
• Historically, Depreciation & Amortization (CF) has averaged $2.4 million across 3 years, with a median of $2.2 million in 2025.
• On a YoY basis, Depreciation & Amortization (CF) climbed as much as 26.97% in 2025 and fell as far as 47.57% in 2025.
• Kestra Medical Technologies' Depreciation & Amortization (CF) stood at $1.9 million in 2024, then gained by 26.97% to $2.4 million in 2025, then declined by 2.02% to $2.3 million in 2026.
• Business Quant data shows KMTS's Depreciation & Amortization (CF) at $2.3 million in Q2 2026, $2.0 million in Q1 2026, and $2.4 million in Q4 2025.